🔎 Trials Near Me

홈 › 식도 선암 › 펜실베이니아

펜실베이니아의 식도 선암 임상 시험

식도 선암 관련 연구 15개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.

펜실베이니아의 도시

공식 연구 텍스트(영어)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • UPMC-Heritage Valley Health System Beaver, Beaver
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • 외 24개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Christiana Care Health System-Concord Health Center, Chadds Ford
  • 외 14개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05677490

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Penn State Milton S. Hershey Medical Center, Hershey
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06324357

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  • Alliance Cancer Specialists, PC, Bensalem
  • Alliance Cancer Specialists, PC, Doylestown
  • Alliance Cancer Specialists, PC, Horsham
  • 외 4개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07392892

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277413

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • University of Pennsylania, Perelman School of Medicine, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중
18세 ~ 89세 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT05753748

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Hershey
  • Research Site, Philadelphia
  • Research Site, Pittsburgh
  • 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT07431281

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Philadelphia
  • Normunity Investigational Site, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07182149

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 15. 업데이트됨 · NCT06657144

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

  • Geisinger Medical Center, Danville
피험자 모집 중
18세 ~ 89세 · 모든 성별 · 2026. 7. 1. 업데이트됨 · NCT05530343

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 23. 업데이트됨 · NCT04114136

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 23. 업데이트됨 · NCT06340711

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 16. 업데이트됨 · NCT07223424

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 1. 21. 업데이트됨 · NCT03539822

ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.